The purpose of this study was to develop an oral nanocarrier as budesonide delivery system and to evaluate its therapeutic potential for inflammatory bowel disease (IBD). The nanoparticles (NPs) based on an amphiphilic inulin polymer with 4-aminothiophenol (ATP) grafted onto carboxymethyl inulin (CMI) were prepared. The particle sizes were about 210.18 nm and had the obvious pH/redox sensitive swelling transitions. The drug-release study of NPs <-- >in vitro showed a low release rate (about 45 wt%) in GSH-free media, whereas high release rate (about 80 wt%) in the media containing 20 mM GSH, exhibiting a redox-responsive property. Further in vivo experiments found the NPs tended to accumulate in inflamed sites, and exerted excellent therapeutic efficacy in comparison to drug suspension in colitis mice model. All the results demonstrated that the redox-sensitive NPs, based on amphiphilic inulin, may be used as colon-targeted drug delivery for the treatment of IBD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.carbpol.2017.12.021 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
As an advanced nucleic acid therapeutical modality, mRNA can express any type of protein in principle and thus holds great potential to prevent and treat various diseases. Despite the success in COVID-19 mRNA vaccines, direct local delivery of mRNA into the lung by inhalation would greatly reinforce the treatment of pulmonary pathogens and diseases. Herein, we developed lipid nanoparticles (LNPs) from degradable ionizable glycerolipids for potent pulmonary mRNA delivery via nebulization.
View Article and Find Full Text PDFLocally Acting Budesonide-Loaded Solid Self-Microemulsifying Drug Delivery Systems (SMEDDS) for Distal Ulcerative Colitis.
Int J Nanomedicine
November 2024
Department of Anatomical Pathology, Faculty of Medicine, University of Alexandria, Alexandria, Egypt.
Background: Budesonide (BUD) is a BCS class II medication with poor water solubility and limited oral bioavailability. In this study, innovative solid self-microemulsifying drug delivery systems (BUD-SMEDDS) were developed for effective local management of distal ulcerative colitis (UC).
Methods: Based on solubility and emulsification tests, the components of the self-microemulsifying drug delivery system (SMEDDS) were Capryol™ 90, Tween 80, and Transcutol HP.
The Design of Novel 3D-Printed, Moulded, and Oral Viscous Budesonide Formulations for Paediatrics: A Comparative Evaluation of Their Mucoadhesive Properties.
Pharmaceutics
October 2024
Departamento de Ingeniería Química y Tecnología Farmacéutica, Campus de Anchieta, Universidad de La Laguna, 38200 La Laguna, Spain.
Background/objectives: Paediatric eosinophilic oesophagitis (EoE) treatment is challenging due to the limited number of age-appropriate formulations. This study aims to develop and evaluate oral viscous suspensions and solid formulations of budesonide (BUD), focusing on their in vitro mucoadhesive properties, to enhance drug delivery and therapeutic outcomes in paediatric EoE.
Methods: This study encompasses the development of oral viscous suspensions and orodispersible solid formulations (moulded tablets and 3D-printed dosage forms) containing BUD.
Formulation and evaluation of carrier-based dry powders containing budesonide and arformoterol for inhalation therapy.
Pharm Dev Technol
November 2024
Department of Pharmacy, Chungbuk National University, Cheongju, Republic of Korea.
Article Synopsis
- Asthma and COPD are significant health issues globally, with inhalation therapy being a key treatment method.
- This study focuses on optimizing dry powder inhalers (DPIs) by addressing particle aggregation through advanced techniques, aiming to enhance drug delivery efficiency of formulations combining budesonide and Arformoterol.
- Results showed that optimized formulations resulted in substantial therapeutic improvements in asthma models, with AFT demonstrating similar efficacy to Formoterol at a lower dose, and both drugs exhibited promising in vivo behavior and drug delivery efficiency.
The AMSA® manosonic nebulizer for ENT disease among children in Poland.
Int J Pediatr Otorhinolaryngol
November 2024
Department of Audiology and Phoniatric Clinic, World Hearing Centre of the Institute of Physiology and Pathology of Hearing, Warsaw/Kajetany, Poland. Electronic address:
Introduction: The AMSA® manosonic nebulizer uses acoustic vibration and a flow of air to create an aerosol from a solution or suspension of a drug. The aerosol created this way is claimed to have enhanced penetration and drug delivery. It is administered under short-term overpressure, meaning that the aerosol is able to penetrate into the middle ear through the Eustachian tube (ET).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!